This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tochner, Z. Articles by Russo, A. Search for Related Content PubMed PubMed Citation Articles by Tochner, Z. Articles by Russo, A.

Treatment of Murine Intraperitoneal Ovarian Ascitic Tumor with Hematoporphyrin Derivative and Laser Light

Radiation Oncology Branch, Division of Cancer Treatment, National Cancer Institute, NIH [Z. T., J. B. M., F. S. H., D. T. R., A. R.], and Biomedical Engineering and Instrumentation Branch, Division of Research Services, NIH [P. S.], Bethesda, Maryland 20205

An ascitic murine tumor, ovarian embryonal carcinoma, was used as a model of human ovarian carcinoma restricted to the peritoneum. The tumor was treated with a combination of hematoporphyrin derivative (HPD) and i.p. 514-nm laser light. Mice were given injections of 2 x 10⁵ tumor cells, and by 9 days, there were 2 to 4 g of ascitic tumor/mouse. On Day 9, mice (68) were treated as follows: (12) no treatment; (12) only HPD (50 mg/kg i.p.); (12) laser only (9.6 J for 16 min); and (32) HPD (50 mg/kg i.p.) and 2 h later, laser treatment. On Day 15, a second treatment with HPD and laser was given to 15 mice. All mice not receiving HPD-laser treatment died between Days 20 and 23. The response rate as determined by decrease in weight and abdominal size for HPD-laser-treated mice was 90%, but the response was short, and all but one animal died by Day 34. However, 6 of 15 of the twice-treated group are alive at 90 days and considered cured. Photoradiotherapy with HPD for i.p. ascitic tumors appears to have promise as a treatment modality.

¹ To whom requests for reprints should be addressed, at Radiation Oncology Branch, National Cancer Institute, Building 10, Room B3-B69, Bethesda, Maryland 20205.

Received 12/ 3/84. Revised 2/27/85. Accepted 3/27/85.

This article has been cited by other articles:

				G. M. Griffin, T. Zhu, M. Solonenko, F. Del Piero, A. Kapakin, T. M. Busch, A. Yodh, G. Polin, T. Bauer, D. Fraker, et al. Preclinical Evaluation of Motexafin Lutetium-mediated Intraperitoneal Photodynamic Therapy in a Canine Model Clin. Cancer Res., February 1, 2001; 7(2): 374 - 381. [Abstract] [Full Text]

				Z. A. Tochner, S. Hahn, and E. Glatstein Photoimmunotherapy and Ovarian Cancer: an Improbable Fiction or a Palpable Hit? J Natl Cancer Inst, September 15, 1999; 91(18): 1526 - 1527. [Full Text] [PDF]

				W. F. Sindelar, T. F. DeLaney, Z. Tochner, G. F. Thomas, L. J. Dachoswki, P. D. Smith, W. S. Friauf, J. W. Cole, and E. Glatstein Technique of Photodynamic Therapy for Disseminated Intraperitoneal Malignant Neoplasms: Phase I Study Arch Surg, March 1, 1991; 126(3): 318 - 324. [Abstract] [PDF]